Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at toppennystockmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. TopPennyStockMovers.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent SANA Stock Price: $4.09
Summary: Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.
Emily Bodnar analyst at H.C. Wainwright reiterates coverage on Sana Biotechnology (SANA) stock in the energy sector with a Hold rating and has not provided SANA's stock price target.
TipRanks.com reports that Sana Biotechnology currently has 2 analysts offering 12-month price targets on SANA and the consensus is a Moderate Buy rating with an average stock price target of $8.00. The most recent SANA stock price we have is $4.09 and we are not making any SANA forecasts at this time.
In addition, TradingView issued a Neutral rating for SANA over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SANA. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SANA, please click here >>
Merus, MRUS
Recent MRUS Stock Price: $23.59
Summary: Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
Yigal Nochomovitz analyst at Citi reiterates coverage on Merus (MRUS) stock in the energy sector with a Buy rating and has set MRUS's stock price target at $44.
TipRanks.com reports that Merus currently has 5 analysts offering 12-month price targets on MRUS and the consensus is a Strong Buy rating with an average stock price target of $45.60. The most recent MRUS stock price we have is $23.59 and we are not making any MRUS forecasts at this time.
In addition, TradingView issued a Neutral rating for MRUS over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRUS. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MRUS, please click here >>
Novo Nordisk, NVO
Recent NVO Stock Price: $100.92
Summary: Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Michael Nedelcovych analyst at TD Cowen reiterates coverage on Novo Nordisk (NVO) stock in the energy sector with a Buy rating and has set NVO's stock price target at $115.
TipRanks.com reports that Novo Nordisk currently has 4 analysts offering 12-month price targets on NVO and the consensus is a Strong Buy rating with an average stock price target of $114.25. The most recent NVO stock price we have is $100.92 and we are not making any NVO forecasts at this time.
In addition, TradingView issued a Neutral rating for NVO over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NVO. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on NVO, please click here >>
Edwards Lifesciences, EW
Recent EW Stock Price: $69.18
Summary: Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Patrick Wood analyst at Morgan Stanley reiterates coverage on Edwards Lifesciences (EW) stock in the energy sector with a Buy rating and has set EW's stock price target at $80.
TipRanks.com reports that Edwards Lifesciences currently has 4 analysts offering 12-month price targets on EW and the consensus is a Moderate Buy rating with an average stock price target of $74.25. The most recent EW stock price we have is $69.18 and we are not making any EW forecasts at this time.
In addition, TradingView issued a buy rating for EW over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on EW. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on EW, please click here >>
Atricure, ATRC
Recent ATRC Stock Price: $36.48
Summary: AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.
Matthew O'Brien analyst at Piper Sandler reiterates coverage on Atricure (ATRC) stock in the energy sector with a Buy rating and has set ATRC's stock price target at $65.
TipRanks.com reports that Atricure currently has 4 analysts offering 12-month price targets on ATRC and the consensus is a Strong Buy rating with an average stock price target of $59.75. The most recent ATRC stock price we have is $36.48 and we are not making any ATRC forecasts at this time.
In addition, TradingView issued a Sell rating for ATRC over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ATRC. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ATRC, please click here >>
Altimmune, ALT
Recent ALT Stock Price: $4.63
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
Seamus Fernandez analyst at Guggenheim reiterates coverage on Altimmune (ALT) stock in the energy sector with a Buy rating and has set ALT's stock price target at $16.
TipRanks.com reports that Altimmune currently has 5 analysts offering 12-month price targets on ALT and the consensus is a Strong Buy rating with an average stock price target of $16.00. The most recent ALT stock price we have is $4.63 and we are not making any ALT forecasts at this time.
In addition, TradingView issued a Strong Buy rating for ALT over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALT. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALT, please click here >>
The editors at toppennystockmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
TopPennyStockMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to TopPennyStockMovers.com.
==============================================================================
